home / stock / mbio / mbio news

MBIO News and Press, Mustang Bio Inc. From 08/13/19

Stock Information
Company Name: Mustang Bio Inc.
Stock Symbol: MBIO
Market: NASDAQ
Website: mustangbio.com
Menu
MBIO MBIO Quote MBIO Short MBIO News MBIO Articles MBIO Message Board
Get MBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
MBIO - Mustang Bio announces $9M grant to fund CAR T study

Thinly traded micro cap Mustang Bio (NASDAQ: MBIO ) announces that the California Institute for Regenerative Medicine has awarded a $9.28M grant to City of Hope to fund an ongoing Phase 1 study of HER2-specific CAR T candidate MB-103 in patients with HER2-positive breast cancer with brain ...
MBIO - Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

MBIO - Mustang Bio to Present at 11th Annual Bioprocessing Summit

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

MBIO - Mustang Bio EPS misses by $0.04

Mustang Bio (NASDAQ: MBIO ): Q2 GAAP EPS of -$0.29 misses by $0.04 . Cash equivalents, short-term investments and restricted cash of $83.1M Press Release More news on: Mustang Bio, Inc., Earnings news and commentary, Healthcare stocks news, ,

MBIO - Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

MBIO - FDA Clears IND for Mustang Bio's MB-102 (CD123 CAR T)

NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

MBIO - Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia

NEW YORK, July 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tum...
MBIO - Mustang Bio +8.6% as Cantor sees 108% upside

Mustang Bio (NASDAQ: MBIO ) is up 8.6% after hours following an initiation at Overweight by Cantor. More news on: Mustang Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...

MBIO - Mustang Bio and St. Jude Children's Research Hospital to Participate in Panel Discussion at Boston CEO 2019

NEW YORK, and MEMPHIS, Tenn., May 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic c...

MBIO - GEVO, TRQ among premarket gainers

Iovance Biotherapeutics (NASDAQ: IOVA ) +36%  on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more ...

Previous 10 Next 10